Among participants with treatmentrelated adverse events 82 were mild or moderate in severity and 4 participants experienced serious treatmentrelated adverse events including 3 participants in the treatment group 2 cases of rhabdomyolysis 2 transaminase elevations and 1 participant in the placebo rhabdomyolysis